Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

By Ph. J. Coles, F.R.C. D. Alastair, F.Med.Sci S. Compston, M. W. Selmaj, Sc.D Stephen L. Lake, M. Susan Moran, David H Margolin M.S.C.E., Kim Norris Ph.D., B. Tandon. New England Journal of Medicine, 2008

1,000 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/abec915e679c6fe13935ccf2b12652a6288268f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. You-Shan Feng
2. T. Kohlmann
3. S. Meyer-Moock
4. M. Maeurer
5. F. Dippel

Citations in the corpus

• Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis (2013, background): “Recent studies usually also include the MSFC-score as an endpoint in clinical trials [39-41].”